News

Filter

Astellas and CoMentis to end Alzheimer’s collaboration

20-10-2014

Japanese drug major Astellas Pharma and US biotech firm CoMentis have said they will end their worldwide…

Astellas PharmaBiotechnologyCoMentisLicensingNeurologicalResearch

AVEO and Astellas finally terminate tivozanib collaboration

14-02-2014

US biotech firm AVEO Oncology and Japanese drug major Astellas Pharma are to end their worldwide collaboration…

Astellas PharmaAVEO OncologyBiotechnologyLicensingOncologytivozanib

AstraZeneca to fork out $815 million for rights to anemia drug candidate

31-07-2013

In yet another move to boost its R&D pipeline, Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered…

Asia-PacificASP1517Astellas PharmaAstraZenecaBiotechnologyFG-4592FibroGenLicensingNephrology and HepatologyNorth AmericaPharmaceuticalResearch

Seattle Genetics takes up option to co-develop additional ADC with Astellas

28-06-2013

Japanese drug major Astellas Pharma (TYO: 4503) says that US biotech firm Seattle Genetics (Nasdaq: SGEN)…

ASG-15MEAstellas PharmaBiotechnologyLicensingOncologyPharmaceuticalSeattle Genetics

Astellas and Cytokinetics collaborate on new frontier of muscle biology

26-06-2013

In a second deal announced this month by US biotech firm, Cytokinetics (Nasdaq: CYTK) has entered into…

Astellas PharmaBiotechnologyCK-2127107CytokineticsLicensingPharmaceuticalResearch

Merck & Co in Nanobody deal with Ablynx; J&J and Astellas join forces on RA

02-10-2012

US pharma giant Merck & Co (NYSE: MRK) has entered into a collaboration with Belgium's Ablynx (Euronext…

AblynxAnti-Arthritics/RheumaticsASPO15KAstellas PharmaBiotechnologyJohnson & JohnsonLicensingMerck & CoPharmaceutical

Astellas in-licenses antibody from Evec; Mitsubishi Tanabe deal with Synageva

06-09-2011

Japanese biotech firm Evec has entered a license agreement for one of its fully-human antibodies against…

Asia-PacificAstellas PharmaBiotechnologyEvecImmunologicalsLicensingMitsubishi TanabePharmaceuticalRare diseasesResearchSynageva BioPharma

Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I

03-09-2010

US biotechnology firm Seattle Genetics (Nasdaq: SGEN) has achieved a milestone under its antibody-drug…

AgensysAstellas PharmaBiotechnologyLicensingOncologyPharmaceuticalResearchSeattle Genetics

COMPANY SPOTLIGHT

Menarini

Back to top